WEDNESDAY, April 30, 2025 (HealthDay News) — Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according to a study published online April 22 in the Annals of Internal Medicine. Using dipeptidyl peptidase-4 inhibitors (DPP4is) as a benchmark, Anil […]
The post Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists first appeared on Physician’s Weekly.
